Here, we showed that the survival of APL leukaemic cells depends on an active PI3K-AKT-mTORC pathway and a transcriptionally inactive FOXO3 signalling axis TG2 dependent manner in the combined treatments. The gene discussed is TGM2; the disease is acute promyelocytic leukemia.